Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.36 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.36 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | PRKCG | P05129 | 1/20 | 0.30 |
| ▸ | PRKCB | P05771 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCH | P24723 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12418703 | 0.82 | LPAR1 (0.42) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL17213404 | 0.80 | USP2 (0.47) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL19566345 | 0.80 | LMNA (0.33) | LPAR1LPAR3LPAR2DNM1SPHK1 | |
| SCHEMBL17916228 | 0.80 | PRKD3 (0.37) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL18544663 | 0.80 | LPAR1 (0.42) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL6246947 | 0.80 | LPAR1 (0.55) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL6246948 | 0.80 | LPAR1 (0.55) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL23171105 | 0.79 | LPAR1 (0.42) | LPAR1LPAR3LPAR2LPAR6LPAR4 | |
| SCHEMBL14225211 | 0.79 | HSD17B10 (0.38) | LPAR1LPAR3LPAR2USP2HSD17B10 | |
| SCHEMBL9613744 | 0.79 | HSD17B10 (0.45) | LPAR1LPAR3LPAR2LPAR6LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653780-B2 | Amino lipids and methods for the delivery of nucleic acids | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-05-19 | — | — | US | disclosed |
| EP-3225621-A1 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | Arbutus Biopharma Corporation (CA) | 2017-10-04 | — | — | EP | disclosed |
| US-20160095924-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-04-07 | — | — | US | disclosed |
| US-20160095924-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-04-07 | — | — | US | disclosed |
| US-9139554-B2 | Amino lipids and methods for the delivery of nucleic acids | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-09-22 | — | — | US | disclosed |
| US-9139554-B2 | Amino lipids and methods for the delivery of nucleic acids | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-09-22 | — | — | US | disclosed |
| EP-2350043-B9 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORP (CA) | 2014-08-20 | — | — | EP | disclosed |
| EP-2350043-B1 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORP (CA) | 2014-03-26 | — | — | EP | disclosed |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-20 | — | — | US | disclosed |
| WO-2010042877-A1 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160095924-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | NSUN3, SARNP, LDLR | LPAR1 80/4885LPAR3 84/4885LPAR2 82/4885 |
| US-10653780-B2 | Amino lipids and methods for the delivery of nucleic acids | NSUN3, SARNP, LDLR | LPAR1 80/4885LPAR3 84/4885LPAR2 82/4885 |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | NSUN3, SARNP, LDLR | LPAR1 80/4885LPAR3 84/4885LPAR2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.